Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...
Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
News Medical3d
HIV drug access remains a major challenge despite promising trial results
Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...
AMD downgraded, Nike upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...
The Bulwark3d
The Best of Times, the Worst of Times for Medicine in America
Our medical tools and techniques are rapidly improving but our system for delivering health care is a source of widespread ...
SciDev3dOpinion
HIV drug access crisis persists despite trial success
Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...
newtelegraphng4d
Who Convenes Experts On Guidelines For New HIV Prevention
ShareThe World Health Organisation (WHO) is assembling a Guideline Development Group (GDG) to craft recommendations for the ...
Managed Healthcare Executive6d
WHO to Develop Lenacapavir and HIV Testing Guidelines
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...